280 related articles for article (PubMed ID: 32081857)
1. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
[TBL] [Abstract][Full Text] [Related]
2. Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer.
Yu X; Gao F; Li W; Zhou L; Liu W; Li M
J Exp Clin Cancer Res; 2020 Apr; 39(1):62. PubMed ID: 32276600
[TBL] [Abstract][Full Text] [Related]
3. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
[TBL] [Abstract][Full Text] [Related]
4. Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.
Li W; Yu X; Tan S; Liu W; Zhou L; Liu H
Cancer Med; 2018 Jan; 7(1):208-218. PubMed ID: 29239135
[TBL] [Abstract][Full Text] [Related]
5. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
[TBL] [Abstract][Full Text] [Related]
6. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.
Jung SK; Lee MH; Lim DY; Kim JE; Singh P; Lee SY; Jeong CH; Lim TG; Chen H; Chi YI; Kundu JK; Lee NH; Lee CC; Cho YY; Bode AM; Lee KW; Dong Z
J Biol Chem; 2014 Dec; 289(52):35839-48. PubMed ID: 25368326
[TBL] [Abstract][Full Text] [Related]
7.
Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
[TBL] [Abstract][Full Text] [Related]
8. Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.
Xie YJ; Gao WN; Wu QB; Yao XJ; Jiang ZB; Wang YW; Wang WJ; Li W; Hussain S; Liu L; Leung EL; Fan XX
Pharmacol Res; 2020 Sep; 159():104934. PubMed ID: 32464330
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological basis and new insights of deguelin concerning its anticancer effects.
Lin ZY; Yun QZ; Wu L; Zhang TW; Yao TZ
Pharmacol Res; 2021 Dec; 174():105935. PubMed ID: 34644595
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171
[TBL] [Abstract][Full Text] [Related]
12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
14. Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.
Li W; Gao F; Ma X; Wang R; Dong X; Wang W
Oncotarget; 2017 May; 8(20):32586-32599. PubMed ID: 28427230
[TBL] [Abstract][Full Text] [Related]
15. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
16. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
17. Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.
Lin L; Ding D; Xiao X; Li B; Cao P; Li S
J Cell Mol Med; 2020 Jun; 24(12):6822-6832. PubMed ID: 32352219
[TBL] [Abstract][Full Text] [Related]
18. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.
Hu C; Wang A; Wu H; Qi Z; Li X; Yan XE; Chen C; Yu K; Zou F; Wang W; Wang W; Wu J; Liu J; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
Oncotarget; 2017 Mar; 8(11):18359-18372. PubMed ID: 28407693
[TBL] [Abstract][Full Text] [Related]
20. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]